136402-32-9

Upstream product

• 907587-41-1 methyl 5-chloro-2-{[(4-chlorophenyl)sulfonyl]amino}benzoate 
• 98-60-2 4-chlorobenzenesulfonyl chloride 
• 635-21-2 5-chloroanthranilic acid 
• 5202-89-1 4-chlorobenzenesulfonyl chloride 

Downstream Products

• 907587-42-2 methyl 4-[(5-chloro-2-{[(4-chlorophenyl)sulfonyl]amino}benzoyl)amino]benzoate 
• 254878-41-6 5-Chloro-2-(4-chloro-phenylsulfonylamino)-N-(4-mercapto-phenyl)-benzamide 
• 254878-31-4 5-Chloro-2-(4-chloro-phenylsulfonylamino)-benzoyl chloride 

Relevant academic research and scientific papers

INHIBITORS OF CCR9 ACTIVITY

Compounds of formula (I), in which R1 and R2 are independently a substituted phenyl group, where the substituents are as defined in the claims and with the proviso that at least one of the substituents is a cyano, carboxy or (C1

Discovery of new chemical leads for selective EP1 receptor antagonists

A series of 4-({2-[alkyl(phenylsulfonyl)amino]phenoxy}methyl)benzoic acids were identified as functional PGE2 antagonists with selectivity for the EP1 receptor subtype starting from a chemical lead 1, which was found while screening our in-house compound library. Discovery of the optimized analogs 21-23 is presented here and structure-activity relationships (SAR) are also discussed.

SULFUR SUBSTITUTED SULFONYLAMINOCARBOXYLIC ACID N-ARYLAMIDES, THEIR PREPARATION, THEIR USE AND PHARMACEUTICAL PREPARATIONS COMPRISING THEM

The present invention relates to compounds of the formula I wherein A1, A2, R1, R2, R3, X and n are as defined in the claims, which are valuable pharmaceutically active compounds for the therapy and prophylaxis of diseases, for example of cardiovascular diseases such as hypertension, angina pectoris, cardiac insufficiency, thromboses or atherosclerosis. The compounds of the formula I are capable of modulating the body’s production of cyclic guanosine monophosphate (cGMP) and are generally suitable for the therapy and prophylaxis of diseases which are associated with a disturbed cGMP balance. The invention furthermore relates to processes for preparing compounds of the formula I, to their use for the therapy and prophylaxis of the abovementioned diseases and for preparing pharmaceuticals for this purpose, and to pharmaceutical preparations which comprise compounds of the formula I